Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 13, 2026
TickeronGET DAILY SIGNALS
SHFS vs TCRT: Two Micro-Cap Stories with Diverging Catalysts

SHFS vs TCRT: Two Micro-Cap Stories with Diverging Catalysts

Key Takeaways

  • SHFS (SHF Holdings, operating as Safe Harbor Financial) is a fintech platform serving the cannabis banking sector, while TCRT (Alaunos Therapeutics) is a clinical-stage biopharmaceutical company now repositioned through a reverse merger.
  • Both are micro-cap names trading under $2 per share with significant 52-week declines, but their recent catalysts point in sharply different directions.
  • SHFS recently completed a 1-for-12 reverse stock split and reported accelerating deposit growth, whereas TCRT announced a transformative acquisition of Velaris Therapeutics alongside a $350 million financing.
  • TCRT's restructuring has driven a sharp single-session re-rating and elevated volume, while SHFS remains under downward pressure near 52-week lows.
  • Neither company is currently profitable, and both face meaningful liquidity, dilution, and listing-related risk factors.

Introduction

Placing SHFS alongside TCRT highlights two distinct corners of the speculative small-cap space. One operates as a financial-services platform tied to the evolving cannabis banking niche, while the other is a biopharmaceutical firm navigating a major corporate reset. Given the heavy drawdowns, volatile trading patterns, and event-driven moves both stocks have seen, this comparison appeals most to those tracking micro-cap momentum, restructuring events, and relative performance. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their industries. Breaking down each company’s business model, recent moves, and positioning clarifies the trade-offs between a niche fintech operator and a transforming biotech name.

SHFS Overview and Recent Performance

SHFS, or SHF Holdings, Inc., doing business as Safe Harbor Financial, delivers banking, lending, compliance, and related services to institutions active in the cannabis sector. Its platform handles business checking and savings accounts, commercial lending, courier and vaulting services, plus regulatory compliance tools. The company recently implemented a board-approved 1-for-12 reverse stock split, a step often taken to support share price levels and exchange listing compliance. Around the same time, it released preliminary third-quarter deposit figures showing trailing 14-day average deposits near $119.3 million, up 7.4% from a year earlier. Even with these operational updates, the stock has stayed under pressure and trades near the bottom of its 52-week range after an approximate 99% drop over the past year. Negative earnings, a modest revenue base, and limited institutional ownership continue to influence sentiment.

TCRT Overview and Recent Performance

TCRT, Alaunos Therapeutics, Inc., has historically centered on adoptive TCR-engineered T-cell therapies targeting solid tumors. In recent weeks the company completed the acquisition of Velaris Therapeutics, a privately held developer, in what amounts to a reverse merger, and at the same time closed a $350 million private placement led by Fairmount with participation from other institutional investors. The transaction shifts focus toward Velaris’s pulmonary hypertension program while restructuring the capitalization. The news produced an immediate single-session price jump and trading volume well above average, signaling a clear shift in sentiment. Still, the stock sits substantially lower on a trailing 52-week basis, and the company continues to report minimal revenue alongside net losses, with a previously thin cash position prior to the restructuring.

Head-to-Head Comparison

The companies operate in entirely different sectors and carry distinct risk profiles. SHFS draws recurring fee-based revenue from banking and compliance services, providing a more established though still modest revenue stream linked to cannabis-industry demand. Its primary hurdles involve scaling profitably amid a contracting top line and a share price that prompted the reverse split. In contrast, TCRT currently generates negligible revenue yet is attempting a full business reset via the reverse merger and sizable capital raise, essentially trading near-term earnings visibility for a longer-term clinical pipeline. Momentum has favored TCRT following its restructuring announcement, which produced an abrupt upward re-rating, while SHFS has continued to trend lower despite the improving deposit metrics. Both carry notable dilution and listing risks, though the nature differs: SHFS contends with execution and balance-sheet issues, whereas TCRT faces post-merger integration and early-stage clinical uncertainties.

Tickeron AI Verdict

Based on factors such as trend consistency, catalyst strength, and relative positioning, the quantitative signals point toward TCRT in the present setup. The reverse merger and $350 million financing stand out as a clear, high-impact catalyst paired with a sharp positive price move and elevated volume, elements that models often read as a momentum and sentiment inflection point. SHFS, by comparison, shows a weaker trend profile even with steady operational data. This remains a probabilistic assessment rather than a firm recommendation: TCRT still carries integration, dilution, and clinical-stage risks, and its edge could fade if the post-merger narrative loses buying support. Relative performance and trend consistency currently favor TCRT, though both remain high-risk micro-cap situations.

Exploring AI Trading Tools

From what I see, one practical way to supplement manual review of names like these is through curated AI-driven resources. I’ve found Tickeron’s AI Trading Bots helpful for scanning across strategies and timeframes that align with current conditions, offering a data-oriented layer to the analysis without replacing fundamental judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TCRT, SHFS

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


TCRT in +7.50% Uptrend, rising for three consecutive days on November 18, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TCRT advanced for three days, in 182 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 72 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

TCRT moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for TCRT moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRT as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TCRT turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 10-day moving average for TCRT crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TCRT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.780) is normal, around the industry mean (3.596). P/E Ratio (-0.994) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer treatment company

Industry Biotechnology

Industry
Biotechnology
Address
501 East Las Olas Boulevard
Phone
+1 346 355-4099
Employees
1
Web
https://www.alaunos.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.